Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 10-K Report Annual Report
  2. S-8 Other Securities Offered to Employees in Benefit Plans
  3. 8-K Event Results of operations
  4. 144 Insider Sale of Securities
  5. 144 Insider Sale of Securities
  6. 144 Insider Sale of Securities
  7. 4 Open-market sale President and CEO sold 35,198 shares at $16.50 ($580,767)
  8. 4 Open-market sale COFO and Secretary sold 17,218 shares at $16.50 ($284,097)
  9. 144 Insider Sale of Securities
  10. 144 Insider Sale of Securities
  11. 144 Insider Sale of Securities
  12. 8-K Event Regulation FD disclosure
  13. 4 Grant or award COFO and Secretary acquired 57,700 shares (grant or award)
  14. 4 Grant or award President and CEO acquired 78,960 shares (grant or award)
  15. 4 Derivatives Options or other derivatives
  16. 8-K Event Material agreement · Other events
  17. 424B5 Offering Prospectus
  18. 424B5 Offering Prospectus
  19. 144 Insider Sale of Securities
  20. 8-K Event Regulation FD disclosure · Other events

Page 3 of 40 · 789 filings